Physician profile
David A Estes
NPI 1487658258
$756.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $116 · 2021: $217 · 2022: $224.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $124.98 | 2019-2021 | |
| Pfizer INC. | $115.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $82.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $63.67 | 2021-2022 | |
| Tris Pharma INC | $59.08 | 2022 | |
| Corium, LLC | $58.69 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $54.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.40 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $45.80 | 2019 | |
| Phadia US INC. | $35.84 | 2021-2022 | |
| Abbvie INC. | $19.87 | 2021 | |
| Sobi, INC | $15.83 | 2019 | |
| Neos Therapeutics, LP | $15.43 | 2022 | |
| Adlon Therapeutics L.P. | $11.82 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.